-
1
-
-
78650632464
-
Cardio-oncology/onco-cardiology
-
Hong, R. A., Iimura, T., Sumida, K. N. & Eager, R. M. Cardio-oncology/onco-cardiology. Clin. Cardiol. 12, 733-737 (2010).
-
(2010)
Clin. Cardiol
, vol.12
, pp. 733-737
-
-
Hong, R.A.1
Iimura, T.2
Sumida, K.N.3
Eager, R.M.4
-
2
-
-
0015849162
-
A clinicopathologic analysis of adriamycin cardiotoxicity
-
Lefrak, E. A., Pitha, J., Rosenheim, S. & Gottlieb, J. A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32, 302-314 (1973).
-
(1973)
Cancer
, vol.32
, pp. 302-314
-
-
Lefrak, E.A.1
Pitha, J.2
Rosenheim, S.3
Gottlieb, J.A.4
-
3
-
-
84872599189
-
Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer
-
Henson, K. E., McGale, P., Taylor, C. & Darby, S. C. Radiation-related mortality from heart disease and lung cancer more than 20 years after radiotherapy for breast cancer. Br. J. Cancer 108, 179-182 (2013).
-
(2013)
Br. J. Cancer
, vol.108
, pp. 179-182
-
-
Henson, K.E.1
McGale, P.2
Taylor, C.3
Darby, S.C.4
-
4
-
-
32144448027
-
Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment
-
Ewer, M. et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J. Clin. Oncol. 23, 7820-7826 (2005).
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 7820-7826
-
-
Ewer, M.1
-
5
-
-
84877741007
-
The hibernating myocardium: Current concepts, diagnostic dilemmas, and clinical challenges in the post-STICH era
-
Shah, B. N., Khattar, R. S. & Senior, R. The hibernating myocardium: current concepts, diagnostic dilemmas, and clinical challenges in the post-STICH era. Eur. Heart J. 34, 1323-1336 (2013).
-
(2013)
Eur. Heart J.
, vol.34
, pp. 1323-1336
-
-
Shah, B.N.1
Khattar, R.S.2
Senior, R.3
-
6
-
-
79955777649
-
Ku70 and Rad51 vary in their importance for repair of doxorubicin-versus etoposide-induced DNA damage
-
Schonn, I., Hennesen, J. & Dartsch, D. C. Ku70 and Rad51 vary in their importance for repair of doxorubicin-versus etoposide-induced DNA damage. Apoptosis 16, 359-369 (2011).
-
(2011)
Apoptosis
, vol.16
, pp. 359-369
-
-
Schonn, I.1
Hennesen, J.2
Dartsch, D.C.3
-
7
-
-
0018102512
-
Anthracycline cardiomyopathy monitored by morphologic changes
-
Billingham, M. E., Mason, J. W., Bristow, M. R. & Daniels, J. R. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. 62, 865-872 (1978).
-
(1978)
Cancer Treat. Rep
, vol.62
, pp. 865-872
-
-
Billingham, M.E.1
Mason, J.W.2
Bristow, M.R.3
Daniels, J.R.4
-
8
-
-
84893493110
-
Cardiac complications of chemotherapy: Role of biomarkers
-
Colombo, A., Sandri, M. T., Salvatici, M., Cipolla, C. M. & Cardinale, D. Cardiac complications of chemotherapy: role of biomarkers. Curr. Treat. Options. Cardiovasc. Med. 16, 313-326 (2014).
-
(2014)
Curr. Treat. Options. Cardiovasc. Med
, vol.16
, pp. 313-326
-
-
Colombo, A.1
Sandri, M.T.2
Salvatici, M.3
Cipolla, C.M.4
Cardinale, D.5
-
9
-
-
74049092701
-
Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase
-
Kerkela, R. et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin. Transl. Sci. 2, 15-25 (2009).
-
(2009)
Clin. Transl. Sci
, vol.2
, pp. 15-25
-
-
Kerkela, R.1
-
10
-
-
19444378256
-
Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity
-
Ewer, M. S. & Lippman, S. M. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J. Clin. Oncol. 23, 2900-2902 (2005).
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 2900-2902
-
-
Ewer, M.S.1
Lippman, S.M.2
-
11
-
-
84927671972
-
Cancer treatment-related cardiotoxicity: Current state of knowledge and future research priorities
-
Shelburne, N. et al. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J. Natl. Cancer Inst. 106, dju232 (2014).
-
(2014)
J. Natl. Cancer Inst
, vol.106
, pp. dju232
-
-
Shelburne, N.1
-
12
-
-
84877995039
-
The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients
-
Hall, P. S., Harshman, L. C., Srinivas, S. & Witteles, R. M. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 1, 72-78 (2013).
-
(2013)
JACC Heart Fail
, vol.1
, pp. 72-78
-
-
Hall, P.S.1
Harshman, L.C.2
Srinivas, S.3
Witteles, R.M.4
-
13
-
-
84923853767
-
Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: Quantitative radiologic assessment and implications for management
-
Kim, K. W. et al. Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for management. Korean J. Radiol. 16, 304-313 (2015).
-
(2015)
Korean J. Radiol
, vol.16
, pp. 304-313
-
-
Kim, K.W.1
-
14
-
-
84904070535
-
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events
-
Ewer, M. S. et al. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur. J. Cancer 50, 2162-2170 (2014).
-
(2014)
Eur. J. Cancer
, vol.50
, pp. 2162-2170
-
-
Ewer, M.S.1
-
15
-
-
0026031848
-
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
-
Lipshultz, S. E. et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N. Engl. J. Med. 324, 808-815 (1999).
-
(1999)
N. Engl. J. Med
, vol.324
, pp. 808-815
-
-
Lipshultz, S.E.1
-
16
-
-
0018716636
-
Risk factors for doxorubicin-induced congestive heart failure
-
Von Hoff, D. D. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91, 710-717 (1979).
-
(1979)
Ann. Intern. Med
, vol.91
, pp. 710-717
-
-
Von Hoff, D.D.1
-
17
-
-
0018194325
-
Clinical spectrum of anthracycline antiobiotic cardiotoxicity
-
Bristow, M. R., Billingham, M. E., Mason, J. W. & Daniels, J. R. Clinical spectrum of anthracycline antiobiotic cardiotoxicity. Cancer Treat. Rep. 62, 865-872 (1978).
-
(1978)
Cancer Treat. Rep
, vol.62
, pp. 865-872
-
-
Bristow, M.R.1
Billingham, M.E.2
Mason, J.W.3
Daniels, J.R.4
-
18
-
-
0017755691
-
Adriamycin cardiomyopathy-risk factors
-
Minow, R. A., Benjamin, R. S., Lee, E. T. & Gottlieb, J. A. Adriamycin cardiomyopathy-risk factors. Cancer 39, 1397-1402 (1977).
-
(1977)
Cancer
, vol.39
, pp. 1397-1402
-
-
Minow, R.A.1
Benjamin, R.S.2
Lee, E.T.3
Gottlieb, J.A.4
-
19
-
-
0038521374
-
Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials
-
Swain, S. M., Whaley, F. S. & Ewer, M. S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97, 2869-2879 (2013).
-
(2013)
Cancer
, vol.97
, pp. 2869-2879
-
-
Swain, S.M.1
Whaley, F.S.2
Ewer, M.S.3
-
20
-
-
84907352671
-
Prevention of anthracycline-induced cardiotoxicity
-
Vejpongsa, P. & Yeh, E. T. Prevention of anthracycline-induced cardiotoxicity. J. Am. Coll. Cardiol. 64, 936-945 (2014).
-
(2014)
J. Am. Coll. Cardiol
, vol.64
, pp. 936-945
-
-
Vejpongsa, P.1
Yeh, E.T.2
-
21
-
-
0018150114
-
Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice
-
Pacciarini, M. A. et al. Distribution and antitumor activity of adriamycin given in a high-dose and a repeated low-dose schedule to mice. Cancer Treat. Rep. 62, 791-800 (1978).
-
(1978)
Cancer Treat. Rep
, vol.62
, pp. 791-800
-
-
Pacciarini, M.A.1
-
22
-
-
0020684494
-
Effect of anthracycline antibiotics on oxygen radical formation in rat heart
-
Doroshow, J. H. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 43, 460-472 (1983).
-
(1983)
Cancer Res
, vol.43
, pp. 460-472
-
-
Doroshow, J.H.1
-
23
-
-
84869209094
-
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
-
Zhang, S. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639-1642 (2012).
-
(2012)
Nat. Med
, vol.18
, pp. 1639-1642
-
-
Zhang, S.1
-
24
-
-
1542349778
-
Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes
-
Lim, C. C. et al. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J. Biol. Chem. 279, 8290-8299 (2004).
-
(2004)
J. Biol. Chem
, vol.279
, pp. 8290-8299
-
-
Lim, C.C.1
-
25
-
-
33644806519
-
Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies
-
Wouters, K. A. et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 131, 561-578 (2005).
-
(2005)
Br. J. Haematol
, vol.131
, pp. 561-578
-
-
Wouters, K.A.1
-
26
-
-
84871560746
-
Using cardiac biomarkers and treating cardiotoxicity in cancer
-
Colombo, A. & Cardinale, D. Using cardiac biomarkers and treating cardiotoxicity in cancer. Future Cardiol. 1, 105-118 (2010).
-
(2010)
Future Cardiol
, vol.1
, pp. 105-118
-
-
Colombo, A.1
Cardinale, D.2
-
27
-
-
0021356510
-
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin
-
Ewer, M. S. et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J. Clin. Oncol. 2, 112-117 (1984).
-
(1984)
J. Clin. Oncol
, vol.2
, pp. 112-117
-
-
Ewer, M.S.1
-
28
-
-
84906834548
-
Expert Consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
-
Plana, J. C. et al. Expert Consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 27, 911-939 (2014).
-
(2014)
J. Am. Soc. Echocardiogr
, vol.27
, pp. 911-939
-
-
Plana, J.C.1
-
29
-
-
80053539103
-
Adjuvant trastuzumab in HER2-positive breast cancer
-
Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365, 1273-1283 (2010).
-
(2010)
N. Engl. J. Med
, vol.365
, pp. 1273-1283
-
-
Slamon, D.1
-
30
-
-
41649083764
-
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
-
Perez, E. A. et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J. Clin. Oncol. 26, 1231-1238 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, pp. 1231-1238
-
-
Perez, E.A.1
-
31
-
-
29744442709
-
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
-
Tan-Chiu, E. et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. 23, 7811-7819 (2005).
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 7811-7819
-
-
Tan-Chiu, E.1
-
32
-
-
79960013901
-
Onco-cardiology: The time has come
-
Yeh, E. T. Onco-cardiology: the time has come. Tex. Heart Inst. J. 38, 246-247 (2011).
-
(2011)
Tex. Heart Inst. J.
, vol.38
, pp. 246-247
-
-
Yeh E. ., T.1
-
33
-
-
53049098067
-
Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity
-
Fan, L. et al. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet. Genomics 18, 621-631 (2008).
-
(2008)
Pharmacogenet. Genomics
, vol.18
, pp. 621-631
-
-
Fan, L.1
-
34
-
-
77957306355
-
Cardiotoxicity of anticancer treatments: What the cardiologist needs to know
-
Ewer, M. S. & Ewer, S. M. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat. Rev. Cardiol. 7, 564-575 (2010).
-
(2010)
Nat. Rev. Cardiol
, vol.7
, pp. 564-575
-
-
Ewer, M.S.1
Ewer, S.M.2
-
35
-
-
77957355941
-
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: Long-term follow-up of a prospective, randomized, multicenter trial
-
Lipshultz, S. E. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomized, multicenter trial. Lancet Oncol. 11, 950-961 (2010).
-
(2010)
Lancet Oncol
, vol.11
, pp. 950-961
-
-
Lipshultz, S.E.1
-
36
-
-
84923104065
-
Deep inspiration breath-hold technique for left-sided breast cancer: An analysis of predictors for organ at risk sparing
-
Register, S. et al. Deep inspiration breath-hold technique for left-sided breast cancer: an analysis of predictors for organ at risk sparing. Med. Dosim. 40, 89-95 (2015).
-
(2015)
Med. Dosim
, vol.40
, pp. 89-95
-
-
Register, S.1
-
37
-
-
0020039397
-
Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer
-
Legha, S. S. et al. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 49, 1762-1766 (1982).
-
(1982)
Cancer
, vol.49
, pp. 1762-1766
-
-
Legha, S.S.1
-
38
-
-
0027099925
-
Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer
-
Buzdar, A. U. et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J. Clin Oncol. 10, 1540-1546 (1992).
-
(1992)
J. Clin Oncol
, vol.10
, pp. 1540-1546
-
-
Buzdar, A.U.1
-
39
-
-
84870555288
-
Continuous versus bolus infusion of doxorubicin in children with ALL: Long-term cardiac outcomes
-
Lipshultz, S. E. et al. Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes. Pediatrics 130, 1003-1011 (2012).
-
(2012)
Pediatrics
, vol.130
, pp. 1003-1011
-
-
Lipshultz, S.E.1
-
41
-
-
85047287257
-
Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer
-
Pisano, C. et al. Clinical trials with pegylated liposomal doxorubicin in the treatment of ovarian cancer. J. Drug Deliv. http://dx.doi.org/10.1155/2013/898146.
-
J. Drug Deliv
-
-
Pisano, C.1
-
42
-
-
0024531769
-
A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer
-
Hortobagyi, G. N. et al. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am. J. Clin. Oncol. 12, 57-62 (1989).
-
(1989)
Am. J. Clin. Oncol
, vol.12
, pp. 57-62
-
-
Hortobagyi, G.N.1
-
43
-
-
42749100219
-
Different anthracycline derivatives for reducing cardiotoxicity in cancer patients
-
van Dalen, E. C., Caron, H. N. & Kremer, L. C. Different anthracycline derivatives for reducing cardiotoxicity in cancer patients. Cochrane Database Syst. Rev. 4, CD005006 (2006).
-
(2006)
Cochrane Database Syst. Rev
, vol.4
, pp. CD005006
-
-
Van Dalen, E.C.1
Caron, H.N.2
Kremer, L.C.3
-
44
-
-
0032977942
-
Phase i trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer
-
Sparano, J. A. et al. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. J. Clin. Oncol. 17, 880-886 (1999).
-
(1999)
J. Clin. Oncol
, vol.17
, pp. 880-886
-
-
Sparano, J.A.1
-
45
-
-
0030904096
-
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
-
Swain, S. M. et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 15, 1318-1332 (1997).
-
(1997)
J. Clin. Oncol
, vol.15
, pp. 1318-1332
-
-
Swain, S.M.1
-
46
-
-
0026496068
-
Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin
-
Hochster, H. et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J. Natl. Cancer Inst. 84, 1725-1730 (1992).
-
(1992)
J. Natl. Cancer Inst
, vol.84
, pp. 1725-1730
-
-
Hochster, H.1
-
47
-
-
33845402341
-
Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition
-
Cardinale, D. et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114, 2472-2481 (2006).
-
(2006)
Circulation
, vol.114
, pp. 2472-2481
-
-
Cardinale, D.1
-
48
-
-
33845206791
-
Protective effects of carvedilol against anthracycline-induced cardiomyopathy
-
Kalay, N. et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol. 48, 2258-2262 (2006).
-
(2006)
J. Am. Coll. Cardiol
, vol.48
, pp. 2258-2262
-
-
Kalay, N.1
-
49
-
-
84878731843
-
Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: The OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)
-
Bosch, X. et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J. Am. Coll. Cardiol. 61, 2355-2362 (2013).
-
(2013)
J. Am. Coll. Cardiol
, vol.61
, pp. 2355-2362
-
-
Bosch, X.1
-
50
-
-
84881105772
-
Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis
-
Kalam, K. & Marwick, T. H. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. Eur. J. Cancer 49, 2900-2909 (2013).
-
(2013)
Eur. J. Cancer
, vol.49
, pp. 2900-2909
-
-
Kalam, K.1
Marwick, T.H.2
-
51
-
-
84864000921
-
Decline in the use of anthracyclines for breast cancer
-
Giordano, S. H., Lin, Y. L., Kuo, Y. F., Hortobagyi, G. N. & Goodwin, J. S. Decline in the use of anthracyclines for breast cancer. J. Clin. Oncol. 30, 2232-2239 (2012).
-
(2012)
J. Clin. Oncol
, vol.30
, pp. 2232-2239
-
-
Giordano, S.H.1
Lin, Y.L.2
Kuo, Y.F.3
Hortobagyi, G.N.4
Goodwin, J.S.5
-
52
-
-
0024422886
-
Mitoxantrone: Its development and role in clinical practice
-
Weiss, R. B. Mitoxantrone: its development and role in clinical practice. Oncology 3, 135-141 (1989).
-
(1989)
Oncology
, vol.3
, pp. 135-141
-
-
Weiss R. ., B.1
-
53
-
-
0021822513
-
Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: An update
-
Benjamin, R. S. et al. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. Invest. New Drugs 3, 117-121 (1985).
-
(1985)
Invest. New Drugs
, vol.3
, pp. 117-121
-
-
Benjamin, R.S.1
-
54
-
-
85066565734
-
-
FDA Novantrone®full prescribing information [online]
-
FDA Novantrone®full prescribing information [online] http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/019297s030s031lbl.pdf (2008).
-
(2008)
-
-
-
55
-
-
84897022202
-
Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high dose etoposide stem cell mobilization regimens with N-terminal pro B type natriuretic peptide
-
Ozkan, H. A., Bal, C. & Gulbas, Z. Assessment and comparison of acute cardiac toxicity during high-dose cyclophosphamide and high dose etoposide stem cell mobilization regimens with N-terminal pro B type natriuretic peptide. Transfus. Apher. Sci. 50, 46-52 (2014).
-
(2014)
Transfus. Apher. Sci
, vol.50
, pp. 46-52
-
-
Ozkan, H.A.1
Bal, C.2
Gulbas, Z.3
-
56
-
-
84948007710
-
Cardiotoxicity associated with high-dose cyclophosphamide therapy
-
Gottdiener, J. S. et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch. Intern. Med. 141, 758-763 (1981).
-
(1981)
Arch. Intern. Med
, vol.141
, pp. 758-763
-
-
Gottdiener, J.S.1
-
57
-
-
74049164266
-
The vulnerability of the heart as a pluricellular paracrine organ: Lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy
-
De Keulenaer, G. W., Doggen, K. & Lemmens, K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ. Res. 106, 35-46 (2010).
-
(2010)
Circ. Res
, vol.106
, pp. 35-46
-
-
De Keulenaer, G.W.1
Doggen, K.2
Lemmens, K.3
-
58
-
-
0037172982
-
Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy
-
Ozcelik, C. et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA 99, 8880-8885 (2002).
-
(2002)
Proc. Natl. Acad. Sci. USA
, vol.99
, pp. 8880-8885
-
-
Ozcelik, C.1
-
59
-
-
0036099675
-
ErbB2 is essential in the prevention of dilated cardiomyopathy
-
Crone, S. A. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 8, 459-465 (2002).
-
(2002)
Nat. Med
, vol.8
, pp. 459-465
-
-
Crone, S.A.1
-
60
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
-
(2001)
N. Engl. J. Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
-
61
-
-
84907352671
-
Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities
-
Vejpongsa, P. & Yeh, E. T. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J. Am. Coll. Cardiol. 64, 938-945 (2014).
-
(2014)
J. Am. Coll. Cardiol
, vol.64
, pp. 938-945
-
-
Vejpongsa, P.1
Yeh, E.T.2
-
62
-
-
34548152541
-
Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility
-
Telli, M. L., Hunt, S. A., Carlson, R. W. & Guardino, A. E. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J. Clin. Oncol. 25, 3525-3533 (2007).
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 3525-3533
-
-
Telli, M.L.1
Hunt, S.A.2
Carlson, R.W.3
Guardino, A.E.4
-
63
-
-
33748642331
-
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M. D. Anderson Cancer Center experience
-
Guarneri, V. et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M. D. Anderson Cancer Center experience. J. Clin. Oncol. 24, 4107-4115 (2006).
-
(2006)
J. Clin. Oncol
, vol.24
, pp. 4107-4115
-
-
Guarneri, V.1
-
64
-
-
34548481766
-
111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity
-
de Korte, M. A. et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur. J. Cancer 43, 2046-2051 (2007).
-
(2007)
Eur. J. Cancer
, vol.43
, pp. 2046-2051
-
-
De Korte, M.A.1
-
65
-
-
84876526107
-
Cancer drugs and the heart: Importance and management
-
Suter, T. M. & Ewer, M. S. Cancer drugs and the heart: importance and management. Eur. Heart J. 34, 102-111 (2013).
-
(2013)
Eur. Heart J.
, vol.34
, pp. 102-111
-
-
Suter, T.M.1
Ewer, M.S.2
-
66
-
-
84869125207
-
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer
-
Romond, E. H. et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 30, 3792-3799 (2012).
-
(2012)
J. Clin. Oncol
, vol.30
, pp. 3792-3799
-
-
Romond, E.H.1
-
67
-
-
84905858933
-
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)
-
de Azambuja, E. et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J. Clin. Oncol. 32, 2159-2165 (2014).
-
(2014)
J. Clin. Oncol
, vol.32
, pp. 2159-2165
-
-
De Azambuja, E.1
-
68
-
-
84875421601
-
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: A randomized, double-blind, placebo-controlled phase III study
-
Swain, S. M. et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 18, 257-264 (2013).
-
(2013)
Oncologist
, vol.18
, pp. 257-264
-
-
Swain, S.M.1
-
69
-
-
84903638071
-
Safety profile of pertuzumab with trastuzumab and docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: Results from the phase III trial CLEOPATRA
-
Swain, S. M. et al. Safety profile of pertuzumab with trastuzumab and docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. Oncologist 7, 693-701 (2014).
-
(2014)
Oncologist
, vol.7
, pp. 693-701
-
-
Swain, S.M.1
-
70
-
-
84880229916
-
Trastuzumab emtansine in the treatment of HER-2 positive metastatic breast cnacer patients
-
Bighin, C., Pronzato, P. & Del Mastro, L. Trastuzumab emtansine in the treatment of HER-2 positive metastatic breast cnacer patients. Future Oncol. 9, 955-957 (2013).
-
(2013)
Future Oncol
, vol.9
, pp. 955-957
-
-
Bighin, C.1
Pronzato, P.2
Del Mastro, L.3
-
71
-
-
44949253343
-
Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials
-
Perez, E. A. et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin. Proc. 83, 679-686 (2008).
-
(2008)
Mayo Clin. Proc
, vol.83
, pp. 679-686
-
-
Perez, E.A.1
-
72
-
-
79953907016
-
Principal long-term adverse effects of imatinib in patients with chronic meloid leukemia in chronic phase
-
Mughal, T. I. & Schrieber, A. Principal long-term adverse effects of imatinib in patients with chronic meloid leukemia in chronic phase. Biologics 4, 315-323 (2010).
-
(2010)
Biologics
, vol.4
, pp. 315-323
-
-
Mughal, T.I.1
Schrieber, A.2
-
73
-
-
84901601715
-
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: Final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study
-
Baccarani, M. et al. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int. J. Hematol. 99, 616-624 (2014).
-
(2014)
Int. J. Hematol
, vol.99
, pp. 616-624
-
-
Baccarani, M.1
-
74
-
-
34548030470
-
Congestive heart failure is a rare event in patients receiving imitinib therapy
-
Atallah, E. et al. Congestive heart failure is a rare event in patients receiving imitinib therapy. Blood 110, 1233-1237 (2007).
-
(2007)
Blood
, vol.110
, pp. 1233-1237
-
-
Atallah, E.1
-
75
-
-
33746845181
-
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
-
Kerkelä R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12, 908-916 (2006).
-
(2006)
Nat. Med
, vol.12
, pp. 908-916
-
-
Kerkelä, R.1
-
76
-
-
84863957259
-
Underestimating cardiac toxicity in cancer trials: Lessons learned? J
-
Witteles, R. M., Telli, M. Underestimating cardiac toxicity in cancer trials: lessons learned? J. Clin. Oncol. 30, 1916-1918 (2012).
-
(2012)
Clin. Oncol
, vol.30
, pp. 1916-1918
-
-
Witteles, R.M.1
Telli, M.2
-
77
-
-
79955767772
-
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib
-
Fini, B. I. et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl. Cancer Inst. 103, 763-773 (2011).
-
(2011)
J. Natl. Cancer Inst
, vol.103
, pp. 763-773
-
-
Fini, B.I.1
-
78
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
-
Sternberg, C. N. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 28, 1061-1068 (2010).
-
(2010)
J. Clin. Oncol
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
-
79
-
-
85069330146
-
Cardiac safety of afatinib: Review of clinical trial data
-
Ewer, M. S., Patel, K., O'Brien, D. & Lorence, R. M. Cardiac safety of afatinib: review of clinical trial data. J. Clin. Oncol. 90 (Suppl.) S47-S48 (2014).
-
(2014)
J. Clin. Oncol
, vol.90
, pp. S47-S48
-
-
Ewer, M.S.1
Patel, K.2
O'Brien, D.3
Lorence, R.M.4
-
80
-
-
55949123335
-
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma
-
Schmidinger, M. et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26, 5204-5212 (2008).
-
(2008)
J. Clin. Oncol
, vol.26
, pp. 5204-5212
-
-
Schmidinger, M.1
-
81
-
-
64849114033
-
Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: Case report and review of the literature
-
Wong, M. K. K. & Jarkowski, A. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature. Pharmacotherapy 29, 473-478 (2009).
-
(2009)
Pharmacotherapy
, vol.29
, pp. 473-478
-
-
Wong, M.K.K.1
Jarkowski, A.2
-
82
-
-
84904757283
-
Chemotherapy-induced cardiotoxicity: Detection, prevention and management
-
Truong, J., Yan, A. T., Cramarossa, G. & Chan, K. K. W. Chemotherapy-induced cardiotoxicity: detection, prevention and management. Can. J. Cardiol. 30, 869-878 (2014).
-
(2014)
Can. J. Cardiol
, vol.30
, pp. 869-878
-
-
Truong, J.1
Yan, A.T.2
Cramarossa, G.3
Chan, K.K.W.4
-
83
-
-
84885842429
-
2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines
-
Yancy, C. W. et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128, 1810-1852 (2013).
-
(2013)
Circulation
, vol.128
, pp. 1810-1852
-
-
Yancy, C.W.1
-
84
-
-
0019427633
-
Radiation heart disease Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3, 500 rads to the heart
-
Brosius, F. C., Waller, B. F. & Roberts, W. C. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3, 500 rads to the heart. Am. J. Med. 70, 519-530 (1981).
-
(1981)
Am. J. Med
, vol.70
, pp. 519-530
-
-
Brosius, F.C.1
Waller, B.F.2
Roberts, W.C.3
-
85
-
-
0027386156
-
Factors affecting late mortality from heart disease after treatment of Hodgkin's disease
-
Hancock, S. L., Tucker, M. A. & Hoppe, R. T. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270, 1949-1955 (1993).
-
(1993)
JAMA
, vol.270
, pp. 1949-1955
-
-
Hancock, S.L.1
Tucker, M.A.2
Hoppe, R.T.3
-
86
-
-
34250703560
-
Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease
-
Heidenreich, P. A. et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J. Clin. Oncol. 25, 43-49 (2007).
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 43-49
-
-
Heidenreich, P.A.1
-
87
-
-
84898003439
-
Cardiovascular complications of radiation therapy for thoracic malignancies: The role for non-invasive imaging for detection of cardiovascular disease
-
Groarke, J. D. et al. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. Eur. Heart J. 35, 612-623 (2014).
-
(2014)
Eur. Heart J.
, vol.35
, pp. 612-623
-
-
Groarke, J.D.1
-
88
-
-
0037212077
-
Radiation-associated cardiovascular disease
-
Adams, M. J., Hardenbergh, P. H. & Constine, L. S. Radiation-associated cardiovascular disease. Crit. Rev. Oncol. Hematol. 45, 55-75 (2003).
-
(2003)
Crit. Rev. Oncol. Hematol
, vol.45
, pp. 55-75
-
-
Adams, M.J.1
Hardenbergh, P.H.2
Constine, L.S.3
-
89
-
-
84923559134
-
Radiation-induced heart disease: Pathologic abnormalities and putative mechanisms
-
Taunk, N. K. et al. Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front. Oncol. http://dx.doi.org/10.3389/fonc.2015.00039.
-
Front. Oncol
-
-
Taunk, N.K.1
-
90
-
-
84922967155
-
Valvular abnormalities detected by echocardiography in 5-year survivors of childhood cancer: A long-term follow-up study
-
Van der Pal, H. J. et al. Valvular abnormalities detected by echocardiography in 5-year survivors of childhood cancer: a long-term follow-up study. Int. J. Radiat. Oncol. Biol. Phys. 91, 213-222 (2015).
-
(2015)
Int. J. Radiat. Oncol. Biol. Phys
, vol.91
, pp. 213-222
-
-
Van Der Pal, H.J.1
-
91
-
-
0029850453
-
Post-radiotherapy pericarditis; A clinical and pathological study of 75 cases [French]
-
Loire, R., Fareh. S., Goineau, P., Pinede. L & Bizollon, M. H. Post-radiotherapy pericarditis; a clinical and pathological study of 75 cases [French]. Arch. Mal. Coeur Vaiss. 89, 1357-1362 (1996).
-
(1996)
Arch. Mal. Coeur Vaiss
, vol.89
, pp. 1357-1362
-
-
Loire, R.1
Fareh, S.2
Goineau, P.3
Pinede, L.4
Bizollon, M.H.5
-
92
-
-
84901285869
-
Radiation-induced heart disease: An under-recognized entity? Curr
-
Davis, M. & Witteles, R. M. Radiation-induced heart disease: an under-recognized entity? Curr. Treat. Options Cardiovasc. Med. 16, 317 (2014).
-
(2014)
Treat. Options Cardiovasc. Med
, vol.16
, pp. 317
-
-
Davis, M.1
Witteles, R.M.2
-
93
-
-
45849100875
-
Phase i trial of docetaxel and thalidomide: A regimen based on metronomic therapeutic principles
-
Sanborn, S. L. et al. Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest. New Drugs 26, 355-362 (2008).
-
(2008)
Invest. New Drugs
, vol.26
, pp. 355-362
-
-
Sanborn, S.L.1
-
94
-
-
0035880237
-
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide
-
Westervelt, P. et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98, 266-271 (2001).
-
(2001)
Blood
, vol.98
, pp. 266-271
-
-
Westervelt, P.1
-
95
-
-
84898825699
-
Chemotherapy and QT prolongation: Overview with clinical perspective
-
Kim, P. Y. & Ewer, M. S. Chemotherapy and QT prolongation: overview with clinical perspective. Curr. Treat. Options Cardiovasc. Med. 16, 303 (2014).
-
(2014)
Curr. Treat. Options Cardiovasc. Med
, vol.16
, pp. 303
-
-
Kim, P.Y.1
Ewer, M.S.2
-
96
-
-
84927566218
-
Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure
-
Hai, J. J. et al. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure. Ann. Hematol. 94, 501-503 (2015).
-
(2015)
Ann. Hematol
, vol.94
, pp. 501-503
-
-
Hai, J.J.1
-
97
-
-
84868113707
-
Electrocardiograms (ECGs) in phase i anticancer drug development: The MD Anderson Cancer Center experience with 8518 ECGs
-
Naing, A. et al. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Ann. Oncol. 23, 2960-2963 (2012).
-
(2012)
Ann. Oncol
, vol.23
, pp. 2960-2963
-
-
Naing, A.1
-
98
-
-
66949158016
-
Fluoropyrimidine-associated cardiotoxicity: Revisited
-
Saif, M. W., Shah, M. M. & Shah, A. R. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin. Drug. Saf. 8, 191-202 (2009).
-
(2009)
Expert Opin. Drug. Saf
, vol.8
, pp. 191-202
-
-
Saif, M.W.1
Shah, M.M.2
Shah, A.R.3
-
99
-
-
22144479717
-
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer
-
Ng, M., Cunningham, D. & Norman, A. R. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer. Eur. J. Cancer 41, 1542-1546 (2005).
-
(2005)
Eur. J. Cancer
, vol.41
, pp. 1542-1546
-
-
Ng, M.1
Cunningham, D.2
Norman, A.R.3
-
100
-
-
0027069532
-
Cardiotoxicity of high-dose continuous infusion fluorouracil: A prospective clinical study
-
de Forni, M. et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J. Clin. Oncol. 10, 1795-1801 (1992).
-
(1992)
J. Clin. Oncol
, vol.10
, pp. 1795-1801
-
-
De Forni, M.1
-
101
-
-
34548141828
-
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
-
Scappaticci, F. A. et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J. Natl. Cancer Inst. 99, 1232-1239 (2007).
-
(2007)
J. Natl. Cancer Inst
, vol.99
, pp. 1232-1239
-
-
Scappaticci, F.A.1
-
102
-
-
70349413045
-
Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The RRiTE observational study
-
Kozloff, M. et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the RRiTE observational study. Oncologist 14, 862-870 (2009).
-
(2009)
Oncologist
, vol.14
, pp. 862-870
-
-
Kozloff, M.1
-
103
-
-
77957576145
-
Troponin i provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction
-
Ewer, M. S. & Ewer, S. M. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J. Clin. Oncol. 28, 3901-3904 (2010).
-
(2010)
J. Clin. Oncol
, vol.28
, pp. 3901-3904
-
-
Ewer, M.S.1
Ewer, S.M.2
-
104
-
-
33344478381
-
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
-
Joensuu, H. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809-820 (2006).
-
(2006)
N. Engl. J. Med
, vol.354
, pp. 809-820
-
-
Joensuu, H.1
-
105
-
-
34548531901
-
Tratuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial
-
Suter, T. M. et al. Tratuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J. Clin. Oncol. 25, 3859-3865 (2007).
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 3859-3865
-
-
Suter, T.M.1
-
106
-
-
84884418164
-
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial
-
Goldhirsch, A. et al. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382, 1021-1028 (2013).
-
(2013)
Lancet
, vol.382
, pp. 1021-1028
-
-
Goldhirsch, A.1
|